Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Depersonalization/derealization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis

Daphne Simeon, MD
Section Editor
David Spiegel, MD
Deputy Editor
Richard Hermann, MD


Depersonalization/derealization disorder (DDD) is characterized by the persistence or recurrence of depersonalization and/or derealization that cause clinically significant distress or impairment in the presence of intact reality testing [1].

Depersonalization is a persistent or recurrent feeling of detachment or estrangement from one’s self. An individual experiencing depersonalization may report feeling like an automaton or as if in a dream or watching himself or herself in a movie. Depersonalized individuals may report the sense of being an outside observer of their mental processes or their body. They often report feeling a loss of control over their thoughts, perceptions, and actions.

Derealization is a subjective sense of detachment or unreality regarding the world around them (eg, individuals or objects are experienced as unreal, dreamlike, foggy, lifeless, or visually distorted).

DDD has a prevalence of approximately two percent and is associated with significant morbidity, but often goes undetected or misdiagnosed, leading to delays in treatment.

This topic discusses the epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of DDD. Treatment of DDD is discussed separately. (See "Treatment of depersonalization/derealization disorder".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Aug 27, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington 2013.
  2. Cattell JP, Cattell JS. Depersonalization: Psychological and social perspectives. In: American Handbook of Psychiatry, Arieti S. (Ed), Basic Books, New York 1974.
  3. Aderibigbe YA, Bloch RM, Walker WR. Prevalence of depersonalization and derealization experiences in a rural population. Soc Psychiatry Psychiatr Epidemiol 2001; 36:63.
  4. Ross CA, Joshi S, Currie R. Dissociative experiences in the general population: a factor analysis. Hosp Community Psychiatry 1991; 42:297.
  5. Hunter EC, Sierra M, David AS. The epidemiology of depersonalisation and derealisation. A systematic review. Soc Psychiatry Psychiatr Epidemiol 2004; 39:9.
  6. Simeon D, Knutelska M, Nelson D, Guralnik O. Feeling unreal: a depersonalization disorder update of 117 cases. J Clin Psychiatry 2003; 64:990.
  7. Baker D, Hunter E, Lawrence E, et al. Depersonalisation disorder: clinical features of 204 cases. Br J Psychiatry 2003; 182:428.
  8. Noyes R Jr, Hoenk PR, Kuperman S, Slymen DJ. Depersonalization in accident victims and psychiatric patients. J Nerv Ment Dis 1977; 164:401.
  9. Noyes R Jr, Kletti R. Depersonilization in response to life-threatening danger. Compr Psychiatry 1977; 18:375.
  10. Simeon D, Guralnik O, Schmeidler J, et al. The role of childhood interpersonal trauma in depersonalization disorder. Am J Psychiatry 2001; 158:1027.
  11. Simeon D, Giesbrecht T, Knutelska M, et al. Alexithymia, absorption, and cognitive failures in depersonalization disorder: a comparison to posttraumatic stress disorder and healthy volunteers. J Nerv Ment Dis 2009; 197:492.
  12. Grigsby J, Kaye K. Incidence and correlates of depersonalization following head trauma. Brain Inj 1993; 7:507.
  13. Simeon D, Kozin DS, Segal K, Lerch B. Is depersonalization disorder initiated by illicit drug use any different? A survey of 394 adults. J Clin Psychiatry 2009; 70:1358.
  14. Simeon D. Depersonalisation disorder: a contemporary overview. CNS Drugs 2004; 18:343.
  15. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57:270.
  16. Deakin JF, Lees J, McKie S, et al. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 2008; 65:154.
  17. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 1998; 87:1186.
  18. Mathew RJ, Wilson WH, Chiu NY, et al. Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand 1999; 100:67.
  19. Feigenbaum JJ, Bergmann F, Richmond SA, et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci U S A 1989; 86:9584.
  20. Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 2001; 157:151.
  21. Simeon D, Hollander E, Stein DJ, et al. Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine. Psychiatry Res 1995; 58:161.
  22. Southwick SM, Krystal JH, Bremner JD, et al. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1997; 54:749.
  23. D'Souza DC, Gil RB, Zuzarte E, et al. gamma-Aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation. Biol Psychiatry 2006; 59:128.
  24. Sierra M, Senior C, Dalton J, et al. Autonomic response in depersonalization disorder. Arch Gen Psychiatry 2002; 59:833.
  25. Simeon D, Guralnik O, Knutelska M, et al. Basal norepinephrine in depersonalization disorder. Psychiatry Res 2003; 121:93.
  26. Stanton BR, David AS, Cleare AJ, et al. Basal activity of the hypothalamic-pituitary-adrenal axis in patients with depersonalization disorder. Psychiatry Res 2001; 104:85.
  27. Simeon D, Knutelska M, Yehuda R, et al. Hypothalamic-pituitary-adrenal axis function in dissociative disorders, post-traumatic stress disorder, and healthy volunteers. Biol Psychiatry 2007; 61:966.
  28. Blanke O, Ortigue S, Landis T, Seeck M. Stimulating illusory own-body perceptions. Nature 2002; 419:269.
  29. Simeon D, Guralnik O, Hazlett EA, et al. Feeling unreal: a PET study of depersonalization disorder. Am J Psychiatry 2000; 157:1782.
  30. Phillips ML, Medford N, Senior C, et al. Depersonalization disorder: thinking without feeling. Psychiatry Res 2001; 108:145.
  31. Lemche E, Surguladze SA, Giampietro VP, et al. Limbic and prefrontal responses to facial emotion expressions in depersonalization. Neuroreport 2007; 18:473.
  32. Lanius RA, Vermetten E, Loewenstein RJ, et al. Emotion modulation in PTSD: Clinical and neurobiological evidence for a dissociative subtype. Am J Psychiatry 2010; 167:640.
  33. Simeon D, Abugel J. Feeling Unreal: Depersonalization Disorder and the Loss of the Self, Oxford University Press, New York 2006.
  34. Hunter EC, Phillips ML, Chalder T, et al. Depersonalisation disorder: a cognitive-behavioural conceptualisation. Behav Res Ther 2003; 41:1451.
  35. Simeon D, Abugel J. Feeling Unreal: Depersonalization disorder and the loss of self, Oxford University Press, New York 2006.
  36. Sierra M, Baker D, Medford N, David AS. Unpacking the depersonalization syndrome: an exploratory factor analysis on the Cambridge Depersonalization Scale. Psychol Med 2005; 35:1523.
  37. Simeon D, Kozin DS, Segal K, et al. De-constructing depersonalization: further evidence for symptom clusters. Psychiatry Res 2008; 157:303.
  38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington DC 2000.
  39. Simeon D, Guralnik O. Dissection of schizotypy and dissociation in depersonalization disorder. J Trauma and Dissociation 2004; 5:111.
  40. Lambert MV, Senior C, Fewtrell WD, et al. Primary and secondary depersonalisation disorder: a psychometric study. J Affect Disord 2001; 63:249.
  41. Sierra M, Lopera F, Lambert MV, et al. Separating depersonalisation and derealisation: the relevance of the "lesion method". J Neurol Neurosurg Psychiatry 2002; 72:530.
  42. Medford N, Baker D, Hunter E, et al. Chronic depersonalization following illicit drug use: a controlled analysis of 40 cases. Addiction 2003; 98:1731.
  43. Bernstein EM, Putnam FW. Development, reliability, and validity of a dissociation scale. J Nerv Ment Dis 1986; 174:727.
  44. Bernstein-Carlson E, Putnam FW. An update on the Disssociative Experiences Scale. Dissociation 1993; 6:16.
  45. van Ijzendoorn MH, Schuengel C. The measurement of dissociation in normal and clinical populations: meta-analytic validation of the dissociative experiences scale (DES). Clin Psychol Rev 1996; 16:365.
  46. Sierra M, Berrios GE. The Cambridge Depersonalization Scale: a new instrument for the measurement of depersonalization. Psychiatry Res 2000; 93:153.